Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes
NCT ID: NCT00399711
Last Updated: 2017-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
560 participants
INTERVENTIONAL
2006-11-30
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
NCT00819741
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
NCT00491725
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
NCT00568984
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
NCT00832481
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
NCT01489644
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repaglinide and metformin combination tablet
rosiglitazone and metformin combination tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c between 7.5-11.0% on monotherapy or
* HbA1c between 7.0-10.0% on dual therapy
* BMI maximum 45 kg/m2
Exclusion Criteria
* Severe heart disease
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452), MD
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Vestavia Hills, Alabama, United States
Novo Nordisk Investigational Site
Glendale, Arizona, United States
Novo Nordisk Investigational Site
Mesa, Arizona, United States
Novo Nordisk Investigational Site
Jonesboro, Arkansas, United States
Novo Nordisk Investigational Site
Chula Vista, California, United States
Novo Nordisk Investigational Site
Long Beach, California, United States
Novo Nordisk Investigational Site
Los Angeles, California, United States
Novo Nordisk Investigational Site
Poway, California, United States
Novo Nordisk Investigational Site
Redlands, California, United States
Novo Nordisk Investigational Site
Sacramento, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Diego, California, United States
Novo Nordisk Investigational Site
San Mateo, California, United States
Novo Nordisk Investigational Site
Spring Valley, California, United States
Novo Nordisk Investigational Site
Colorado Springs, Colorado, United States
Novo Nordisk Investigational Site
Hamden, Connecticut, United States
Novo Nordisk Investigational Site
Stamford, Connecticut, United States
Novo Nordisk Investigational Site
Aventura, Florida, United States
Novo Nordisk Investigational Site
Clearwater, Florida, United States
Novo Nordisk Investigational Site
Daytona Beach, Florida, United States
Novo Nordisk Investigational Site
Inverness, Florida, United States
Novo Nordisk Investigational Site
Jacksonville, Florida, United States
Novo Nordisk Investigational Site
Jacksonville, Florida, United States
Novo Nordisk Investigational Site
Jacksonville, Florida, United States
Novo Nordisk Investigational Site
Longwood, Florida, United States
Novo Nordisk Investigational Site
Ocala, Florida, United States
Novo Nordisk Investigational Site
Orlando, Florida, United States
Novo Nordisk Investigational Site
Plantation, Florida, United States
Novo Nordisk Investigational Site
Tampa, Florida, United States
Novo Nordisk Investigational Site
West Palm Beach, Florida, United States
Novo Nordisk Investigational Site
Atlanta, Georgia, United States
Novo Nordisk Investigational Site
Columbus, Georgia, United States
Novo Nordisk Investigational Site
Marietta, Georgia, United States
Novo Nordisk Investigational Site
Honolulu, Hawaii, United States
Novo Nordisk Investigational Site
Nampa, Idaho, United States
Novo Nordisk Investigational Site
Arlington Heights, Illinois, United States
Novo Nordisk Investigational Site
Aurora, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Chicago, Illinois, United States
Novo Nordisk Investigational Site
Flossmoor, Illinois, United States
Novo Nordisk Investigational Site
Naperville, Illinois, United States
Novo Nordisk Investigational Site
Oak Brook, Illinois, United States
Novo Nordisk Investigational Site
Springfield, Illinois, United States
Novo Nordisk Investigational Site
Vernon Hills, Illinois, United States
Novo Nordisk Investigational Site
Indianapolis, Indiana, United States
Novo Nordisk Investigational Site
Des Moines, Iowa, United States
Novo Nordisk Investigational Site
Shawnee Mission, Kansas, United States
Novo Nordisk Investigational Site
Topeka, Kansas, United States
Novo Nordisk Investigational Site
Erlanger, Kentucky, United States
Novo Nordisk Investigational Site
Louisville, Kentucky, United States
Novo Nordisk Investigational Site
Bossier City, Louisiana, United States
Novo Nordisk Investigational Site
Baltimore, Maryland, United States
Novo Nordisk Investigational Site
Hyattsville, Maryland, United States
Novo Nordisk Investigational Site
Ann Arbor, Michigan, United States
Novo Nordisk Investigational Site
Flint, Michigan, United States
Novo Nordisk Investigational Site
Oak Park, Michigan, United States
Novo Nordisk Investigational Site
Troy, Michigan, United States
Novo Nordisk Investigational Site
Kansas City, Missouri, United States
Novo Nordisk Investigational Site
Omaha, Nebraska, United States
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States
Novo Nordisk Investigational Site
Las Vegas, Nevada, United States
Novo Nordisk Investigational Site
Berlin, New Jersey, United States
Novo Nordisk Investigational Site
Jersey City, New Jersey, United States
Novo Nordisk Investigational Site
Warren Township, New Jersey, United States
Novo Nordisk Investigational Site
Rochester, New York, United States
Novo Nordisk Investigational Site
West Seneca, New York, United States
Novo Nordisk Investigational Site
Asheville, North Carolina, United States
Novo Nordisk Investigational Site
Greenville, North Carolina, United States
Novo Nordisk Investigational Site
Raleigh, North Carolina, United States
Novo Nordisk Investigational Site
Salisbury, North Carolina, United States
Novo Nordisk Investigational Site
Wilmington, North Carolina, United States
Novo Nordisk Investigational Site
Winston-Salem, North Carolina, United States
Novo Nordisk Investigational Site
Cincinnati, Ohio, United States
Novo Nordisk Investigational Site
Franklin, Ohio, United States
Novo Nordisk Investigational Site
Tulsa, Oklahoma, United States
Novo Nordisk Investigational Site
Tulsa, Oklahoma, United States
Novo Nordisk Investigational Site
Portland, Oregon, United States
Novo Nordisk Investigational Site
Norristown, Pennsylvania, United States
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania, United States
Novo Nordisk Investigational Site
Springfield, Pennsylvania, United States
Novo Nordisk Investigational Site
Cranston, Rhode Island, United States
Novo Nordisk Investigational Site
East Providence, Rhode Island, United States
Novo Nordisk Investigational Site
Greer, South Carolina, United States
Novo Nordisk Investigational Site
Mt. Pleasant, South Carolina, United States
Novo Nordisk Investigational Site
Simpsonville, South Carolina, United States
Novo Nordisk Investigational Site
Kingsport, Tennessee, United States
Novo Nordisk Investigational Site
Knoxville, Tennessee, United States
Novo Nordisk Investigational Site
Corpus Christi, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Dallas, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Houston, Texas, United States
Novo Nordisk Investigational Site
Midland, Texas, United States
Novo Nordisk Investigational Site
Plano, Texas, United States
Novo Nordisk Investigational Site
San Antonio, Texas, United States
Novo Nordisk Investigational Site
St. George, Utah, United States
Novo Nordisk Investigational Site
Henrico, Virginia, United States
Novo Nordisk Investigational Site
Lebanon, Virginia, United States
Novo Nordisk Investigational Site
Richmond, Virginia, United States
Novo Nordisk Investigational Site
Virginia Beach, Virginia, United States
Novo Nordisk Investigational Site
Milwaukee, Wisconsin, United States
Novo Nordisk Investigational Site
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes Obes Metab. 2009 Oct;11(10):947-52. doi: 10.1111/j.1463-1326.2009.01069.x. Epub 2009 Jun 16.
Raskin P, Lewin A, Reinhardt R, Lyness W; Repaglinide/Metformin Fixed-Dose Combination Study Group. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab. 2009 Sep;11(9):865-73. doi: 10.1111/j.1463-1326.2009.01062.x. Epub 2009 May 19.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN4440-1794
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.